Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: Another insight to allopurinol-related toxicity

Journal of Clinical Rheumatology

Volumn 11, Issue 3, 2005, Pages 129-133

  Perez Ruiz, Fernando ^a   Hernando, Iñaki ^a   Villar, Irama ^a   Nolla, Joan M ^b  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Allopurinol; Gout suppressants; Kidney failure

Indexed keywords

ALLOPURINOL; BENZBROMARONE;

ANEMIA; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EOSINOPHILIA; EPIDERMOLYSIS; FEMALE; FEVER; GLOMERULUS FILTRATION; GOUT; HUMAN; HYPERSENSITIVITY; KIDNEY FUNCTION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; NECROTIZING ARTERITIS; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; URTICARIA;

ALLOPURINOL; CREATININE; DATABASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; GOUT; GOUT SUPPRESSANTS; HUMANS; KIDNEY; KIDNEY DISEASES; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 20844447189     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000164822.98163.22     Document Type: Article

References (25)

1. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002; 14:281-286.
2. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981-983.
3. Emmerson BT, Gordon RB, Thomson DB. Plasma oxypurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26: 445-449.
4. Stamp L, Gow P, Sharples K, et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med. 2000;30: 567-572.
5. Hande KR, Noone RM, Stone WJ. Allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
6. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young patients. Br J Clin Pharmacol. 1999;48:501-509.
7. Mikuls TR, McLean CH, Oliveri J, et al. Quality of indicators for gout management. Arthritis Rheum. 2004;50:937-943.
8. Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830-838.
9. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatimne levels. J Am Soc Nephrol. 2002;13:2140-2144.
10. Cockroft DW, Gault HM. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
11. WHO Collaboratory Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification. Including Defined Daily Doses (DDDs) for Plain Substances. Oslo: World Health Organization; 1993.
12. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effect of furosemide on renal excretion of oxypurinol and purine bases. Metabolism. 2001;50: 241-245.
13. Swan S, Kosravan R, Mayer MD, et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase. Arthritis Rheum. 2003;48:S529.
14. Mayer M, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non purine selective inhibitor of xanthine oxidase, in subjects with renal impairment. Am J Ther. 2005; 12:22-34.
15. Fukunari A, Okamoto K, Nishino T, et al. Y-700: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther. 2004;311:519-528.
16. Hu KT, Matayoshi A, Stevenson FT. Calculation of the estimated creatinine clearance in avoiding drug dosing errors in the older patient. Am J Med Sci. 2001;322:133-136.
17. Wang F, Dupuis JY, Nathan H, et al. An analysis of the association between preoperative renal dysfunction and outcome in cardiac surgery. Chest. 2003;124:1852-1862.
18. Henrich WL, Agodoa LE, Barrett BA, et al. Analgesics and the kidney: summary and recommendations to the scientific advisory board of the National Kidney Foundation from Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis. 1996;27:162-165.
19. Duncan L, Heathcote J, Djurjev O, et al. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant. 2001;16:1042-1046.
20. Adhiyaman V, Asghar M, Oke A, et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and non-steroidal anti-inflammatory drugs. J R Soc Med. 2001;94:657-658.
21. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43:103-108.
22. Swarup A, Sachdeva N, Schumacher HR. Dosing of antirheumatic drugs in renal disease and dialysis. J Clin Rheumatol. 2004;10:190-204.
23. Perez-Ruiz F, Gonzalez-Mielgo FJ, Herrero-Beites AM. Optimisation of the treatment of acute gout. Biodrugs. 2000;13:415-423.
24. Ben-Chetrit E, Levy M. Colchicine: 1988 update. Semin Arthritis Rheum. 1998;28:48-59.
25. Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18:264-269.